Skip to content
Great news for kids: OSSIOfiber® Metal-Free Compression Screws and Trimmable Fixation Nails are now FDA cleared for various bone fractures in children (ages 2-12) and adolescents (ages 12-21). Read More

In Vivo Study of Bio-Integrative OSSIOfiber Plates

← All Posts

The performance and bio-integration of the OSSIOfiber® Intelligent Bone Regeneration Technology has been successfully evaluated for in-bone and soft tissue fixation. The purpose of this in vivo study was to further evaluate the OSSIOfiber® material properties when implanted over the surface of bone, for its bone-implant interface, local tissue response and full bio-integration profile. This study serves as an indicator for the potential of OSSIOfiber as plate fixation for trauma, extremities and pediatrics.

Test Device: OSSIOfiber Plates*

  • 50mmx10mmx2mm plates comprised of OSSIOfiber Intelligent Bone Regeneration Technology with 4 pre-drilled screw holes
  • At the time, OSSIOfiber screws were not readily available for use, thus metal (stainless-steel) cortical screws were utilized to fixate the OSSIOfiber plates onto bone

*Note: OSSIOfiber Plates are not available for sale

Sdfsdfsdffsdfsd
Figure 1: X-ray and surgical image intra-operative showcasing the OSSIOfiber plate implanted onto the tibia.

Methods:

  • Test model: 8 mature female sheep, average weight 70kg
  • Medial approach to the proximal tibia: skin incision followed by blunt dissection down to the bone surface
  • OSSIOfiber plates were placed approximately 3cm distal to the tibial plateau, parallel to the tibial tuberosity and directly on the cortical bone surface, using bi-cortical fixation with four metal screws
  • Standard wound closure was performed
  • Animals were allowed to fully load bear immediately following surgery and were closely monitored for any adverse clinical signs
  • Micro-CT and histopathology evaluation were conducted at 13, 26, 52, 78, and 104 weeks
Image Png 1 Ossio – Naturally Transformative Bone Healing
Figure 2: Cross-section of OSSIOfiber plate’s gradual bio-integration, from 13 weeks through 104 weeks.

At 104 weeks, Micro-CT demonstrates that the OSSIOfiber plates to be essentially fully integrated into the native anatomy.

Results

  • Quiescent, gradual elimination of the OSSIOfiber plates through 104 weeks of implantation
  • No adverse clinical observations or local bone/soft tissue reactions (i.e. local swelling, cyst formation, lameness) were noted through 104 weeks of implantation
  • At 104 weeks, Micro-CT demonstrates the OSSIOfiber plates to be essentially fully integrated into the native anatomy

Conclusion

OSSIOfiber Intelligent Bone Regeneration Technology, as a plate construct fixated on bone, demonstrated the ideal bio-integration profile for a plate fixation device. Gradual integration, restoring the native anatomy without adverse foreign body reactions, allowing the bone to return to the pre-injury state without forming a permanent callus or overgrowth of new bone.

The development of OSSIOfiber screws will enable new plate and screw system solutions that are fully bio-integrative and avoid the costs, risks and burdens of permanent metal hardware removal. Through the engineering and manufacturing capabilities at OSSIO, plate and screw systems comprised of strong and bio-integrative OSSIOfiber can be designed for optimal biomechanical capabilities and for a multitude of fixation applications across trauma, extremities and pediatrics. OSSIO is actively developing and building evidence for OSSIOfiber plate and screw systems.

Data on File at OSSIO.

OSSIOfiber Compression Plates are not yet available for sale. OSSIOfiber Compression Screws are not available for sale outside of the US.

® OSSIO and OSSIOfiber are registered trademarks of OSSIO Ltd. All rights reserved.

DOC0001433 Rev 01 12/2020

Orahn Preiss-Bloom, Founder and Chief Innovation Officer

Orahn Preiss-Bloom, Founder and Chief Innovation Officer

Orahn is the Founder and Chief Innovation Officer at OSSIO. Previously, as founder and COO/CTO of LifeBond, Orahn developed two biosurgical product families to commercial stage and raised $60M, including from Johnson & Johnson Development Corporation. Prior, he was a biomechanics researcher at IDF Institute for Military Physiology and at Columbia University NY, Dept. of Orthopedic Surgery. Orahn has an M.Sc. in biomedical engineering from the Technion, Israel Institute of Technology.

Related Posts

Implant-related artifacts around metallic and bio-integrative screws: a CT scan 3D Hounsfield unit assessment

Christian VandeLune1, Tutku Tazegul1, Samuel J Ahrenholz1, Caleb Iehl1, Victoria Vivtcharenko1, Eli Schmidt1, Kevin N Dibbern1, Hee Young Lee1, Matthieu Lalevee1, Nacime Salomão Barbachan Mansur1, César de César Netto1 1. Department of Orthopedics and Rehabilitation, University of Iowa, Carver College of Medicine, Iowa City-IA, USA. Study performed at Department of Orthopedics and Rehabilitation, University ofContinue reading “Implant-related artifacts around metallic and bio-integrative screws: a CT scan 3D Hounsfield unit assessment”

Department of Orthopedics and Rehabilitation, University of Iowa, Carver College of Medicine, Iowa City-IA, USA. October 4, 2021

White Paper on OSSIOfiber Technology

Our proprietary material technology, OSSIOfiber® Intelligent Bone Regeneration Technology, has unique material composition and structural design that contribute to its strength and optimal bio-integration for orthopedic fixation. Scientific and clinical leaders at OSSIO discuss the science behind OSSIOfiber in this Technology Overview White Paper.  Key Takeaways: Through the material composition and internal architecture, OSSIOfiber isContinue reading “White Paper on OSSIOfiber Technology”

ASPS Webinar

Earn CECH credits by watching this recent webinar, hosted with American Society of Podiatric Surgeons and presenter Bob Baravarian, DPM, FACFAS.  NOW ON-DEMAND WEBINAR: The Science and Clinical Experience with Strong and Bio-Integrative Implant Fixation Speaker: Bob Baravarian, DPM, FACFAS   Hear Dr. Baravarian present on: Science behind the strong and bio-integrative OSSIOfiber Technology First-in-humanContinue reading “ASPS Webinar”

Bob Baravarian, DPM November 3, 2020

Interested in OSSIOfiber®?

Complete the form and an OSSIOfiber® Advisor will get in touch.

Customer Service

For product inquiries or purchasing questions contact 833-781-7373 or email info@ossio.io

Address

Commercial Headquarters
OSSIO Inc
300 Tradecenter Drive, Suite 3690
Woburn, MA, 01801

Science & Manufacturing Center

OSSIO Ltd.
8 HaTochen Street
Cesarea, Israel 3079861

OSSIOfiber® has been used by over 1500 surgeons across the US

Footnotes

1. Data on file at OSSIO 2. Clinical study data on file at OSSIO 3. Kaiser, P.B., Watkins, I., Riedel, M. D., Cronin, P., Briceno, J., Kron, J. Y. (2019). Implant Removal Matrix for the Foot and Ankle Orthopaedic Surgeon. Foot & Ankle Specialist, 12(1), 79-97. https://doi.org/10.1177/1938640018791015 4. Pre-clinical animal studies (in-bone implantation of OSSIOfiber® and PLDLA control in rabbit femurs). Data on File at OSSIO. 5.Haddad, S. F., Helm, M. M., Meath, B., Adams, C., Packianathan, N., & Uhl, R. (2019). Exploring the Incidence, Implications, and Relevance of Metal Allergy to Orthopaedic Surgeons. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 3(4), e023. https://doi.org/10.5435/JAAOSGlobal-D-19-00023